Stratify different patient groups

The lack of efficacy in Phase II clinical trials is a major factor in the overall failure rate of drug candidates. A contributing factor is insufficient investigational study due to patient heterogeneity.

Use PIMS® technology to identify a cohort of patients who respond to your therapy

Inoviem identifies the patient subset that will best respond to the compound.

By working on this select population, Inoviem can provide assurances that your investigational agent will achieve the required pharmacology compared to the placebo.

Understand the Mode of Action of your compound

Identify and validate targets

Choose your lead compound for development

Stratify different patient groups

Define the indication

Identify biomarkers

Bioanalytical services

Need Help